

Publications

Natale G, Fini E, Calabrò PF, Carli M, Scarselli M, Bocci G (2023). **Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors?** *Cancer Letters*, 2023 Mar 11:216125.

Carli M, Weiss F, Grenno G, Ponzini S, Kolachalam S, Vaglini F, Viaggi C, Pardini C, Tidona S, Longoni B, Maggio R, Scarselli M (2023). **Pharmacological Strategies for Bipolar Disorders in Acute Phases and Chronic management with a special focus on Lithium, Valproic Acid, and Atypical Antipsychotics.** *Current Neuropharmacology*, 2023 Feb 24.

Brancati GE, De Dominicis F, Petrucci A, Pallucchini A, Carli M, Medda P, Schiavi E, De Rossi P, Vicari S, Perugi G (2023). **Long-term treatment of adult ADHD in a naturalistic setting: clinical predictors of attrition, medication choice, improvement, and response.** *World Journal of Biological Psychiatry*, 2023 Jan 13;1-25.

Weiss F, Tidona S, Carli M, Perugi G, Scarselli M (2022). **Triple Diagnosis of Attention-Deficit/Hyperactivity Disorder with Coexisting Bipolar and Alcohol Use Disorders: Clinical Aspects and Pharmacological Treatments.** *Current Neuropharmacology*, 2022 Oct 21.

Cruz-Sanabria F, Carmassi C, Bruno S, Bazzani A, Carli M, Scarselli M, Faraguna U (2023). **Melatonin as a Chronobiotic with Sleep-promoting Properties.** *Current Neuropharmacology*, 2022 Feb 17.

Fasciani I, Carli M, Petragnano F, Colaianni F, Aloisi G, Maggio R, Scarselli M, Rossi M (2022). **GPCRs in Intracellular Compartments: New Targets for Drug Discovery.** *Biomolecules*, 2022, 12(10), 1343.

Frau R, Devoto P, Aroni S, Saba P, Sagheddu C, Siddi C, Santoni M, Carli M, Gessa GL (2022). **The potent α_2 -adrenoceptor antagonist RS 79948 also inhibits dopamine D₂-receptors: Comparison with atipamezole and raclopride.** *Neuropharmacology*, 2022 Oct 1;217:109192.

Petragnano F, Fasciani I, Mannoury la Cour C, di Cara B, Aloisi G, Carli M, Kolachalam S, Rossi M, Marampon F, Scarselli M, Millan MJ, Maggio R (2022). **Interaction of the preferential D₃ agonist (+)PHNO with dopamine D₃-D₂ receptor heterodimers and diverse classes of monoamine receptor: relevance for PET imaging.** *European Journal of Pharmacology*, 15;925:175016.

Carli M, Risaliti E, Francomano M, Kolachalam S, Longoni B, Bocci G, Maggio R, Scarselli M (2022). **A 5-Year Study of Lithium and Valproic Acid Drug Monitoring in Patients with Bipolar Disorders in an Italian Clinical Center.** *Pharmaceuticals*, 2022, 15(1), 105

Maggio R, Fasciani I, Carli M, Petragnano F, Marampon F, Rossi M, Scarselli M (2021). **Integration and spatial organization of signaling by g protein-coupled receptor homo-and heterodimers.** *Biomolecules*, 11(12), 1828.

Carli M, Vaglini F, Risaliti E, Citi G, Masini M, Kolachalam S, Maggio R, Corsini GU, Novelli M, De Tata V, Scarselli M (2021). **β -Cells Different Vulnerability to the Parkinsonian Neurotoxins Rotenone, 1-Methyl-4-phenylpyridinium (MPP⁺) and 6-Hydroxydopamine (6-OHDA).** *Pharmaceuticals*, 14(8), 767

Pallucchini A, Carli M, Maremmani AGI, Scarselli M, Perugi G, Maremmani I (2021). **Influence of Substance Use Disorder on Treatment Retention of Adult-Attention-Deficit/Hyperactive Disorder Patients. A 5-Year Follow-Up Study.** *Journal of Clinical Medicine*, 10(9):1984.

Spera V, Pallucchini A, Carli M, Maiello M, Maremmani AGI, Perugi G, Maremmani I (2021). **Does Cannabis, Cocaine and Alcohol Use Impact Differently on Adult Attention Deficit/Hyperactivity Disorder Clinical Picture?** *Journal of Clinical Medicine*, 10(7):1481.

Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, Aringhieri S, Fasciani I, Annibale P, Maggio R, Scarselli M (2021). **Atypical antipsychotics and metabolic syndrome: From molecular mechanisms to clinical differences.** *Pharmaceuticals*, 14(3), 238.

Pallucchini A, Carli M, Scarselli M, Maremmani I, Perugi G (2021). **Symptomatological variants and related clinical features in adult attention deficit hyperactive disorder.** *International Journal of Environmental Research and Public Health*, 18(3), 1-13, 922.

Carli M, Aringhieri S, Kolachalam S, Longoni B, Grenno G, Rossi M, Gemignani A, Fornai F, Maggio R, Scarselli M (2021). **Is adult hippocampal neurogenesis really relevant for the treatment of psychiatric disorders?** *Current Neuropharmacology*, 2021;19(10):1640-1660.

Fasciani I, Petragnano F, Aloisi G, Marampon F, Carli M, Scarselli M, Maggio R, Rossi M (2020). **Allosteric modulators of G protein-coupled dopamine and serotonin receptors: A new class of atypical antipsychotics.** *Pharmaceuticals*, 13(11), 1-26.

Carli M, Donnini S, Pellegrini C, Coppi E, Bocci G (2020). **Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulation.** *Pharmacological Research*, 159,104938.

Spera V, Pallucchini A, Maiello M, Carli M, Maremmani AGI, Perugi G, Maremmani, I (2020). **Substance Use Disorder in Adult-Attention Deficit Hyperactive Disorder Patients: Patterns of Use and Related Clinical Features.** *International Journal of Environmental Research and Public Health*, 17(10).

Maremmani I, Spera V, Maremmani AGI, Carli M, Scarselli M (2019). **Is Trazodone Contramid Useful in Inducing Patients to Refrain from Using Cocaine after Detoxification, so Avoiding Early Relapse? A Case Series.** *Addictive Disorders and their Treatment*, 18(2);105-112.

Lovrecic B, Lovrecic M, Gabrovec B, Carli M, Pacini M, Maremmani AGI, Maremmani I (2019). **Non-Medical Use of Novel Synthetic Opioids: A New Challenge to Public Health.** *Interantional Journal of Environmental Research and Public Health*, 16(2)

Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M, McCormick PJ, Corsini GU, Maggio R, Scarselli M (2018). **Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences.** *Pharmacology and Therapeutics*, 192:20-41

Carli M, Kolachalam S, Aringhieri S, Rossi M, Giovannini L, Maggio R, Scarselli M (2018). **Dopamine D2 receptors dimers: how can we pharmacologically target them?** *Current Neuropharmacology*, 16(2), 222-230.

Aringhieri S, Kolachalam S, Gerace C, Carli M, Verdesca V, Brunacci MG, Rossi C, Ippolito C, Solini A, Corsini GU, Scarselli M (2017). **Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: Role of 5-HT_{2A} receptor agonism.** *European Neuropsychopharmacology*, 27(4), 383-398